Venlafaxine Treatment of Fibromyalgia

Annals of Pharmacotherapy

Volumn 37, Issue 11, 2003, Pages 1561-1565

  Sayar, Kemal ^a,b   Aksu, Gokhan ^a   Ak, Ismail ^a   Tosun, Mehmet ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^b KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Antidepressants; Fibromyalgia; Venlafaxine

Indexed keywords

ANXIOLYTIC AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; ANOREXIA; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; DEPRESSION; DRUG EFFICACY; FEMALE; FIBROMYALGIA; HEADACHE; HUMAN; IRRITABILITY; MALE; MENTAL DISEASE; MONOAMINERGIC SYSTEM; NAUSEA; NEUROTRANSMITTER RELEASE; PAIN; PHYSICAL DISABILITY; PRIORITY JOURNAL; RATING SCALE; RECEPTOR BLOCKING; SCORING SYSTEM; SIDE EFFECT;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ANXIETY; CYCLOHEXANOLS; DEPRESSION; FEMALE; FIBROMYALGIA; HUMANS; PAIN; SEROTONIN UPTAKE INHIBITORS;

EID: 0142151471     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D112     Document Type: Article

References (28)

1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72.
2. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19-28.
3. Cebi A. [The prevalence and sociodemographic characteristics of fibromyalgia in Trabzon region] Turkish. (dissertation). Trabzon: Karadeniz Technical University Medical School, 2001.
4. Goldenberg DL. Fibromyalgia syndrome a decade later: what have we learned? Arch Intern Med 1999;159:777-85.
5. Ahles TA, Khan SA, Yunus MB, Spiegell DA, Masi AT. Psychiatric status of patients with primary fibromyalgia, patients with rheumatoid arthritis and subjects without pain: a blind comparison of DSM-III diagnoses. Am J Psychiatry 1991;148:1721-6.
6. Arnold LM, Keck PE Jr, Welge JA. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics 2000;41:104-13.
7. O'Malley PG, Balden E, Tomkins G, Santoro J, Kroenke K, Jackson JL. Treatment of fibromyalgia with antidepressants: a meta-analysis. J Gen Intern Med 2000;15:659-66.
8. Norregaard J, Volkmann H, Danneskiold-Samso B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain 1995; 61:445-9.
9. Anderberg UM, Marteinsdottir I, von Knorring L. Citalopram in patients with fibromyalgia - a randomized, double-blind, placebo-controlled study. Eur J Pain 2000;4:27-35.
10. Wolfe F, Cathey MA, Hawley DJ. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 1994;23:255-9.
11. Goldenberg DL, Mayskiy M, Mossey C, Ruthazer R, Schmid C. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996;39:1852-9.
12. Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE, Keck PE Jr. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 2002; 112:191-7.
13. Dwight MM, Arnold LM, O'Brien H, Metzger R, Morris-Park E, Keck PE Jr. An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics 1998;39:14-7.
14. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for the DSM-IV Axis I Disorders - patient edition (SCID-I/P, version 2.0). New York: Biometrics Research Department, New York State Psychiatric Institute, 1995.
15. First MB, Spitzer RL, Gibbon M, Williams JBW: DSM-IV Eksen I Bozukluklari Icin Yapilandirilmis Klinik Gorusme. [Translated by A Corapcioglu]. Ankara: Hekimler Yayin Birligi, 1995.
16. Beck AT, Waed CH, Mendelson M. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-71.
17. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988; 56:893-7.
18. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
19. Hamilton M. The assessment of anxiety disorders by rating. Br J Med Psychol 1959;32:50-65.
20. Burckhardt CS, Clark SR, Bennett RM. The Fibromyalgia Impact Questionnaire: development and validation. J Rheumatol 1991;18:728-33.
21. Hujkisson HC. Visual analog scales. In: Handbook of psychiatric measures. Washington, DC: American Psychiatric Press, 2000:601-3.
22. Sarmer S, Ergin S, Yavuzer G. The validity and reliability of the Turkish version of the Fibromyalgia Impact Questionnaire. Rheumatol Int 2000; 20:9-12.
23. Hisli N. [The reliability and validity study of the Beck Depression Inventory in a Turkish sample] Turkish. Psikoloji Dergisi 1988;6:118-22.
24. Ulusoy M, Sahin NH, Erkmen H. Turkish version of the Beck Anxiety Inventory: psychometric properties. J Cognitive Psychother 1998;12: 163-72.
25. Yazici MK, Demir B, Tanriverdi N, Karaagaoglu E, Yolac P. [Hamilton anxiety scale, inter-rater reliability and validity study] Turkish. Turk Psikiyatri Dergisi 1998;9:114-7.
26. Akdemir A, Turkcapar MH, Orsel SD, Demirergi N, Dag I, Ozbay MH. Reliability and validity of the Turkish version of the Hamilton Depression Rating Scale. Compr Psychiatry 2001;42:161-5.
27. Eberhard G, von Knorring L, Nilsson HL, Sundequist U, Bjorling G, Linder H, et al. A double-blind randomized study of clomipramine and maprotiline in patients with idiopathic pain syndromes. Neuropsychobiology 1988;19:25-34.
28. Miller LJ, Kubes KL. Serotonergic agents in the treatment of fibromyalgia syndrome. Ann Pharmacother 2002;36:707-12. DOI10.1345/aph.1A184